Related references
Note: Only part of the references are listed.Vascular disrupting effect of CKD-516: preclinical study using DCE-MRI
Kyung Won Kim et al.
INVESTIGATIONAL NEW DRUGS (2013)
Anticancer Therapy by Tumor Vessel Infarction with Polyethylene Glycol Conjugated Retargeted Tissue Factor
Christian Schwoeppe et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Nanoparticle Delivered Vascular Disrupting Agents (VDAs): Use of TNF-Alpha Conjugated Gold Nanoparticles for Multimodal Cancer Therapy
Mithun M. Shenoi et al.
MOLECULAR PHARMACEUTICS (2013)
Pharmacodynamics, tissue distribution, toxicity studies and antitumor efficacy of the vascular targeting fusion toxin VEGF121/rGel
Khalid A. Mohamedali et al.
BIOCHEMICAL PHARMACOLOGY (2012)
Combretastatin A-4 Phosphate Affects Tumor Vessel Volume and Size Distribution as Assessed Using MRI-Based Vessel Size Imaging
Thomas Nielsen et al.
CLINICAL CANCER RESEARCH (2012)
Targeted Systemic Radiotherapy with scVEGF/177Lu Leads to Sustained Disruption of the Tumor Vasculature and Intratumoral Apoptosis
Francis G. Blankenberg et al.
JOURNAL OF NUCLEAR MEDICINE (2011)
Molecular mechanisms and clinical applications of angiogenesis
Peter Carmeliet et al.
NATURE (2011)
Nanoparticles that communicate in vivo to amplify tumour targeting
Geoffrey von Maltzahn et al.
NATURE MATERIALS (2011)
Detection of Tumor Response to a Vascular Disrupting Agent by Hyperpolarized 13C Magnetic Resonance Spectroscopy
Sarah E. Bohndiek et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Tumor Blood Volume Determination by Using Susceptibility-corrected ΔR2☆ Multiecho MR
Thorsten Persigehl et al.
RADIOLOGY (2010)
Tissue-factor fusion proteins induce occlusion of tumor vessels
Christian Schwoeppe et al.
THROMBOSIS RESEARCH (2010)
Infarction of tumor vessels by NGR-peptide-directed targeting of tissue factor: experimental results and first-in-man experience
Ralf Bieker et al.
BLOOD (2009)
Treatment of Rodent Liver Tumor With Combretastatin A4 Phosphate Noninvasive Therapeutic Evaluation Using Multiparametric Magnetic Resonance Imaging in Correlation With Microangiography and Histology
Huaijun Wang et al.
INVESTIGATIVE RADIOLOGY (2009)
In vivo optical imaging of CD13/APN-expression in tumor xenografts
Angelika von Wallbrunn et al.
JOURNAL OF BIOMEDICAL OPTICS (2008)
Antiangiogenic tumor treatment: Early noninvasive monitoring with USPIO-enhanced MR imaging in mice
Thorsten Persigehl et al.
RADIOLOGY (2007)
Monitoring the treatment efficacy of the vascular disrupting agent CA4P
Beth A. Salmon et al.
EUROPEAN JOURNAL OF CANCER (2007)
Vascular endothelial growth factor and its receptor as drug targets in hematological malignancies
Torsten Kessler et al.
CURRENT DRUG TARGETS (2007)
Immunogenic and structural properties of the Asn-Gly-Arg (NGR) tumor neovasculature-homing motif
P Di Matteo et al.
MOLECULAR IMMUNOLOGY (2006)
Synergistic antitumor activity of cisplatin, paclitaxel, and gemcitabine with tumor vasculature-targeted tumor necrosis factor-alpha
A Sacchi et al.
CLINICAL CANCER RESEARCH (2006)
Effects of the tumor vasculature targeting agent NGR-TNF on the tumor microenvironment in murine lymphomas
HWM van Laarhoven et al.
INVESTIGATIONAL NEW DRUGS (2006)
Angiogenesis as a therapeutic target
N Ferrara et al.
NATURE (2005)
Inhibition of tumor growth by RGD peptide-directed delivery of truncated tissue factor to the tumor vasculature
T Kessler et al.
CLINICAL CANCER RESEARCH (2005)
In vitro and in vivo studies on continuous echo-contrast application strategies using sonovue in a newly developed rotating pump setup
S Lohmaier et al.
ULTRASOUND IN MEDICINE AND BIOLOGY (2004)
Crucial role for interferon γ in the synergism between tumor vasculature-targeted tumor necrosis factor α (NGR-TNF) and doxorubicin
A Sacchi et al.
CANCER RESEARCH (2004)
Tumor regression by targeted gene delivery to the neovasculature
JD Hood et al.
SCIENCE (2002)
Contrast-enhanced blood-pool MR angiography with optimized iron oxides: Effect of size and dose on vascular contrast enhancement in rabbits
T Allkemper et al.
RADIOLOGY (2002)
Targeting tumor vasculature with homing peptides from phage display
E Ruoslahti
SEMINARS IN CANCER BIOLOGY (2000)
Enhancement of tumor necrosis factor a antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13)
F Curnis et al.
NATURE BIOTECHNOLOGY (2000)
Suppression of angiogenesis by lentiviral delivery of PEX, a noncatalytic fragment of matrix metalloproteinase 2
A Pfeifer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Share Paper
